20/20 Biolabs, Inc. (AIDX)

20/20 Biolabs will go public soon, but the exact IPO date is still unknown.

Stock Price: Pending

IPO price not available yet

20/20 Biolabs Financials Overview

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2024	FY 2023
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Revenue	2.04	1.75	1.42
Revenue Growth	-	23.03%	-
Gross Profit	0.64	0.36	0.11
Operating Income	-3.68	-5.68	-6.57
Net Income	-3.68	-5.55	-6.39

Cash & Debt

Fiscal Year	Current	FY 2024	FY 2023
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Cash & Investments	1.14	1.78	4.09
Total Debt	1.16	0.84	1.23
Net Cash (Debt)	-0.01	0.94	2.86
Net Cash Growth	-	-66.94%	-

Cash Flow & CapEx

Fiscal Year	TTM	FY 2024	FY 2023
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Operating Cash Flow	-1.94	-2.6	-4.48
Capital Expenditures	0	-	-0.04
Free Cash Flow	-1.94	-2.6	-4.52
Free Cash Flow Growth	-	-	-

Margins

Fiscal Year	TTM	FY 2024	FY 2023
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Gross Margin	31.19%	20.56%	7.66%
Operating Margin	-180.05%	-323.99%	-461.31%
Pretax Margin	-180.14%	-316.81%	-448.73%
Profit Margin	-180.14%	-316.81%	-448.73%
FCF Margin	-95.18%	-148.30%	-317.61%